December
Supernus Pharmaceuticals files for $100 million IPO
Washington Business Journal
Rockville-based Supernus Pharmaceuticals Inc. filed Thursday for a $100 million initial public offering. Read More...
RegeneRx sees last day on NYSE
Washington Business Journal
Rockville-based RegeneRx Biopharmaceuticals Inc. will fall off the New York Stock Exchange Dec. 23 after failing to meet a key NYSE listing requirement, the company said in a Securities and Exchange Commission filing. Read More...
Martek to be acquired by Royal DSM for $1.09B
Baltimore Business Journal
Martek Biosciences Corp., one of the Baltimore-area’s largest biotechs, has agreed to be acquired for $1.09 billion by Dutch vitamin maker Royal DSM N.V. Read More...
Tech council to Frederick lawmakers: Help us grow jobs
Gazette.net
Renée M. Winsky hopes the encouraging messages she's hearing from legislators about the state's bioscience community are more than just pre-session lip service. Read More...
Vanda Pharmaceuticals chairman steps down
Washington Business Journal
Vanda Pharmaceuticals Inc. Chairman Argeris Karabelas has stepped down as chairman of the Rockville biotech, the company said in an SEC filing.
Read More...
Biotech pulls plug on vaccine patch; Gaithersburg unit to slash staff by half
Gazette.net
A Gaithersburg biotech plans to cut its staff in half by next summer, after disappointing clinical trial results prompted its Austrian parent to shut down development of its travelers' diarrhea vaccine patch. Read More...
Novavax moving forward with vaccine study
Bloomberg.com
Novavax Inc. said Thursday it will conduct an early-stage study on its potential vaccine for respiratory syncytial virus, following the resolution of a Food and Drug Administration request. Read More...
BioWatch: Maryland biotechs get FDA clearance for clinical trials
Gazette.net
From depression to ulcers and anthrax infections, a handful of Maryland biotechs have been given the regulatory OK to either launch or resume clinical trials of their experimental treatments. Read More...
Neuralstem stock jumps on FDA depression drug trial approval
Washington Business Journal
Rockville-based Neuralstem Inc. won approval to begin a safety trial for a new treatment for depression, lifting its stock price as much as 23 percent. Read More...
HGS eager to break into elite class of biotechs
WashingtonPost.com
In the spring of 2009, the staff of Human Genome Sciences gathered in an auditorium at the nearby Universities at Shady Grove for one of three companywide meetings held each year. Read More...
Human Genome Sciences: FDA postpones ruling on drug
Gazette.net
Human Genome Sciences, which had expected the Food and Drug Administration to rule Thursday on its application to market a new lupus drug, will have to wait until March, the Rockville biotech announced today. Read More....
November
Baltimore biotech parks grow despite recession
Baltimore Sun
While some sectors of Maryland's economy struggle to shake free of the Great Recession, the biotechnology parks adjacent to Baltimore's two top teaching hospitals stubbornly continue to add laboratories, offices and — most importantly for the city — jobs. Read More
HGS ready to sell lupus drug if FDA approves it
Washington Post
From top executives to clerical workers, much of the staff at Human Genome Sciences took pause last Tuesday to watch a Food and Drug Administration advisory panel deliberate over the company's flagship drug candidate, and ultimately signal its endorsement.. Read More...
Frederick biotech company offers faster testing
Frederick News-Post
Traditional laboratory tests to identify pathogens in food samples are normally a three-step process, with each step taking at least 24 hours. Microbiology International, a local biotech company, can reduce that time to one day. Read More...
FDA Panel Backs Approval of Lupus Drug
The Wall Street Journal
The first new treatment for lupus in more than 50 years passed a key hurdle Tuesday with a 13-2 vote by government advisers favoring approval. The verdict for the drug Benlysta by a Food and Drug Administration advisory panel represents a victory for Human Genome Sciences Inc. Read More...
Bioscience's XX factor
Gazette.net
Phyllis Dillinger always knew she had a passion for financial analysis when she entered the bioscience world at the age of 30, working under the CFO at Sopha Medical. Within two years, she knew she wanted his job. Within five years, she had it, and helped take the Columbia company's sales to $42 million from $1 million by the time she left in 1995. Read More...
Human Genome Sciences stock fluctuates on analyst views
Washington Business Journal
Shares in Human Genome Sciences Inc. pulled back as much as 7 percent a day after an advisory panel recommendation of its lupus drug prompted analyst downgrades and questions about the long-term prospects of the treatment. Read More...
FDA panel backs Human Genome Sciences lupus drug
Washington Business Jounal
Rockville-based Human Genome Sciences Inc. and development partner GlaxoSmithKline PLC won backing Tuesday for their experimental lupus drug from a Food and Drug Administration panel, which recommends approval of the first new drug to treat the disease in more than 50 years.
Read More...
Micromet raises $71M, stock falls
Washington Business Journal
Bethesda-based Micromet, whose stock tumbled after announcing a secondary stock offering last week, has closed on the offering and netted $70.5 million in proceeds. Read More...
FDA staff critiques Human Genome Sciences' Benlysta
Washington Business Journal
Human Genome Sciences Inc.’s Benlysta, a drug that would become the first specific treatment for lupus since the disease was discovered, is effective in treating the autoimmune disorder but didn’t benefit African Americans and carries several safety worries, FDA staff wrote in a review released Friday. Read More...
EntreMed says it is funded through 2011
Washington Business Journal
Rockville-based EntreMed Inc. reported a loss for its latest quarter, and reaffirmed its financial position will fund its operations through 2011.
Read More...
Micromet tumbles on stock offering
Washington Business Journal
Bethesda-based Micromet Inc. tumbled as much as 12 percent in Nasdaq trading Thursday after saying it would sell more shares to the public.
Read More...
Micromet cuts losses to $10.4M
Washington Business Journal
Bethesda-based biotech Micromet Inc. cut its losses for the most recent quarter while adding more than $2 million to its top line. Read More...
Novavax reports $10 million loss
Washington Business Journal
Rockville-based vaccine maker Novavax Inc. posted a third quarter net loss of $10.4 million, or 10 cents per share, citing higher research and development spending for its flu vaccine candidates. Read More...
Biotechs sound out investors at conference
Gazette.net
With national biotech investments sliding to $943.7 million in the third quarter from $1.38 billion in the second quarter, industry representatives sought some perspective from investors during a peer panel group discussion at the 2010 Mid-Atlantic Bio Conference. Read More...
Emergent BioSolutions, Protein Sciences Corp. settle suit
Washington Business Journal
Rockville-based Emergent BioSolutions Inc. and Meriden, Conn.-based Protein Sciences Corp. have settled a dispute over Emergent’s failed acquisition of PSC in 2008. Read More...
Vanda Parmaceuticals posts third-straight profit
Washington Business Journal
Rockville-based Vanda Pharmaceuticals, which had no stream of revenue a year ago, posted its third straight profitable quarter as it continues to collect paychecks from its partnership with Novartis. Read More...
PhRMA, BIO heads reflect on state of industry
Fierce Biotech
A host of representatives from the biotech industry congregated in Bethesda, MD last week for the 2010 Mid-Atlantic Bio Conference, which featured more than 400 companies and 50 qualified investors participating. Read More...
GenVec finds no buyer
Washington Business Journal
Gaithersburg-based GenVec Inc., which said in June it was exploring the sale of the company, says no buyer has come forward. Read More...
October
MacroGenics deal worth up to $2.1B
Gazette.net
MacroGenics has signed a development and commercialization deal with Germany's Boehringer Ingelheim that is worth up to $2.1 billion for the privately held Rockville biotech — and has helped "galvanize the spirit of the company," said CEO Scott Koenig. Read More...
Biotechs pitch to investors
Gazette.net
Region's executives, investors, government officials gather at annual Mid-Atlantic Bio Conference. The annual three-day conference brings together biotech industry leaders, government representatives, executives, researchers, investors, entrepreneurs and professional service companies to provide networking, education — and the possibility of capital. Read More...
PharmAthene hopes to raise $15M in stock offering
Baltimore Business Journal
Biodefense firm PharmAthene Inc. plans to raise about $15 million through its second public offering since July. Read More...
Paragon Bioservices to expand at UMd. Biopark
Baltimore Business Journal
Paragon Bioservices said it plans to double the size of its facilities at the University of Maryland BioPark. The Baltimore research and manufacturer is expanding from 20,000 square feet to 45,000 square feet in the BioPark, where its main office is located. Read More...
United Therapeutics earnings triple to $39.7M
Washington Business Journal
Silver Spring-based United Therapeutics Corp. treated more patients with its drugs last quarter, generating more sales and more profits.
Read More...
Human Genome Sciences narrows loss
Washington Business Journal
Rockville-based Human Genome Sciences Inc., advancing its lead drug candidate for the treatment of lupus, narrowed its quarterly loss. The company had third-quarter revenue of $50.8 million, up sharply from $18.8 million in the same quarter a year ago. Read More...
MacroGenics inks development deal that could yield $2.1B
Washington Business Journal
Rockville-based MacroGenics has signed a development deal with pharmaceutical giant Boehringer Ingelheim that could ultimately be worth more than $2 billion. Read More...
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapy
Fierce Biotech
Boehringer Ingelheim and MacroGenics today jointly announced that they have entered into a global alliance to discover, develop and commercialize antibody-based therapeutics which may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases. These developmental drug candidates will be based on MacroGenics' Dual-Affinity Re-Targeting (DART™) platform and will be directed against up to ten combinations of molecular targets. Read More...
BioWatch: More than 800 expected at bio conference
Gazette.net
CEOs from two Maryland biotech heavyweights will be among the speakers headlining the sixth annual Mid-Atlantic Bio Conference, which kicks off with a reception Wednesday evening in North Bethesda. Read More...
MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
Fierce Pharma
MacroGenics, Inc. and Eli Lilly and Company today announced that the Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab, an investigational biologic under development for the treatment of individuals with recent-onset type 1 diabetes. Read More...
Cytomedix raises $13 million in offering, agreements
Washington Business Journal
Gaithersburg-based biotech Cytomedix Inc. said Friday it has secured $13 million through a registered direct offering and other stock purchase agreements. Read More...
Profectus BioSciences wins $4.4M in grants
Baltimore Business Journal
A Baltimore biotechnology company won more than $4 million in grant money to develop a vaccine to help treat and prevent chronic diseases. Profectus BioSciences Inc. received $3.1 million from the Division of AIDS at the National Institutes of Health. Read More...
GenVec gets $3.5M for HIV research
Washington Business Journal
Gaithersburg-based GenVec Inc. and Science Applications International Corp. will continue their HIV research partnership. SAIC-Frederick, a subsidiary of McLean-based SAIC, operates under a long-term contract with the National Cancer Institute on AIDS research. It has executed its first two-year option under a four year contract with GenVec for $3.5 million. Read More...
Human Genome Sciences junks Zalbin
Washington Business Journal
Rockville-based Human Genome Sciences Inc. and Novartis AG announced Tuesday that they would cease development on the struggling hepatitis C drug Zalbin after receiving a full response from the Food and Drug Administration. Read More...
Seguro Surgical Commercializes Lap Pak Abdominal Packing Platform
Citybizlist
Seguro Surgical, Inc., a NeoTech Incubator company, has taken its latest medical device from in-licensing to commercialization in record time. Seguro licensed its Lap Pak abdominal packing platform technology from The Johns Hopkins University in September 2009 and was registered with the Food and Drug Administration (FDA) on September 3, 2010. Lap Pak is scheduled for its commercial launch at the American College of Surgeons Annual Meeting in Washington, D.C., October 3-7, 2010. Read More...
Human Genome Sciences Receives Complete Response Letter from FDA on ZALBIN(TM) BLA for Chronic Hepatitis C
MarketWatch.com
Human Genome Sciences, Inc. today announced that, as expected, it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for 900-mcg ZALBIN(TM) dosed every two weeks for the treatment of chronic hepatitis C. HGS and Novartis have decided not to develop ZALBIN further. Read More...
September
OpGen Completes $17 Million Series B Financing
Fierce Biotech
OpGen, Inc., a commercial phase genomics company, today announced the successful completion of a $17 million Series B equity financing. The new round of financing was led by jVen Capital with participation from the company's other major investors. Read More...
Emergent BioSolutions: Vaccine contract will diversify federal stockpile
Washington Business Journal
Emergent BioSolutions’ latest vaccine contract with the federal government - worth as much as $186.6 million - doesn’t itself qualify as a “next generation” anthrax countermeasure. But it will provide some diversity to the government’s stockpile as Emergent separately develops its third-gen vaccine, said Emergent President and Chief Operating Officer Dan Abdun-Nabi. Read More...
Micromet initiates trials for leukemia drug
Washington Business Journal
Bethesda-based Micromet Inc. announced Monday that it would begin late-stage European trials for its lead drug candidate, blinatumomab, in adults with a certain type of leukemia. Read More...
Montgomery firms raise $37 million
Gazette.net
Three Montgomery County bioscience companies wrapped up successful financing initiatives this month, landing a total of $36.7 million through private investments and a public offering. Read More...
GlycoMimetics Signs New HQ Lease in Gaithersburg
Citybizlist.com
GlycoMimetics, a privately held biotechnology company that has raised a total of $63 million in three rounds of venture financing, will move to a larger corporate headquarters in Gaithersburg this November. Read More...
EntreMed funded through 2011
Washington Business Journal
Rockville-based EntreMed has raised $5.1 million from a group of private investors, enough funding to keep it in business through 2011, it says.
Read More...
Zyngenia raises $15M in VC funding
Washington Business Journal
Gaithersburg-based Zyngenia Inc. has received another investment from New Enterprise Associates worth $15 million. Read More...
UMd. researcher nets $11.4M NIH grant to study Plavix results
Baltimore Business Journal
A University of Maryland researcher has been awarded $11.4 million by the National Institutes of Health to lead a study of the effectiveness of using drugs that prevent blood clots to treat patients with clogged arteries. Read More...
NIH awards Celsion $200K grant
Washington Business Journal
Maryland's Celsion Corp. received a $200,000 grant from the National Institutes of Health for research and development on drugs used to treat cancer.
Read More...
Nabi Biopharmaceuticals finds manufacturer for nicotine vaccine
Washington Business Journal
If Rockville-based Nabi Biopharmaceuticals wins approval to bring its anti-smoking vaccine to market, it is ready to manufacture it. Read More...
Emergent BioSolutions gets new NIH anthrax contract
Washington Business Journal
Rockville-based Emergent BioSolutions Inc. (NYSE: EBS) gets a base, two-year $9.1 million contract from a National Institutes of Health arm to keep upgrading its federally approved anthrax vaccine. That contract could grow to nearly $29 million if the company hits certain milestones. Read More...
Fifteen Maryland startups receive more than $1 Million from TEDCO
Press Release
The Maryland Technology Development Corporation (TEDCO) announced today that 15 Maryland technology companies have received $1,121,900 total in funding. Each company received approximately $75,000 from TEDCO’s Maryland Technology Transfer and Commercialization Fund (MTTCF). Read More...
August
Medimmune receives complete response letter on Montavizumab
Fierce Biotech
AstraZeneca today announced that MedImmune, its biologics unit, has received a second complete response letter (CRL) on motavizumab from the U.S. Food and Drug Administration (FDA). Read More...
Rachel King named one of the Top 10 Women in Biotech
Fierce Biotech
King was at the helm of GlycoMimetics when the company gathered $38 million from an A-list group of venture companies including Genzyme Ventures, New Enterprise Associates--where she was previously an Executive in Residence--the Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures. The company is currently conducting Phase II trials of the drug. Read More...
Fisher BioServices to add jobs as it expands facility
Gazette.net
Fisher BioServices of Frederick has expanded its 33,000-square-foot facility to 55,000 square feet and plans to add eight jobs. The $3 million expansion is being spearheaded by the National Cancer Institute, which has a $27 million contract with SAIC-Frederick for operating the expanded Fisher facility on Wedgewood Boulevard, according to Dennis Fallen, Fisher's vice president and general manager. Read More...
Mtech biofacility expanding into Montgomery County
Baltimore Business Journal
A biotechnology lab affiliated with the University of Maryland said Wednesday it will expand into Montgomery County, doubling its square footage and staff. The Maryland Technology Enterprise Institute’s Bioprocess Scale-Up Facility, located in College Park, is part of the university’s Biotechnology Research and Education Program. Read More...
In tumultuous year, GenVec lands $13M deal
Gazette.net
GenVec, which was staggered this spring by disappointing results from a pivotal clinical trial of its pancreatic cancer treatment, announced a bit of better news last week, to the tune of about $13 million over the next four years.
Read More...
United BioSource sells for $730M
Washington Business Journal
Medco Health Solutions said Monday it will buy United BioSource, a Bethesda firm that conducts post-approval testing for drugs and medical devices, in a $730 million cash deal. Read More...
OriGene Technologies buys Blue Heron Biotechnology
Washington Business Journal
OriGene Technologies Inc. has acquired Blue Heron Technology to expand its gene synthesis products. Read More...
Emergent to buy Trubion Pharmaceuticals
Washington Business Journal
Rockville-based Emergent BioSolutions Inc. will buy Trubion Pharmaceuticals Inc., a Seattle-based developer of autoimmune disorder and cancer treatments, in a cash and stock deal worth up to $135 million. Read More...
Sucampo losses widen
Washington Business Journal
Sucampo Pharmaceuticals Inc. reported lower revenue and a wider loss for its latest quarter on lower research payments from a drug development partner. Read More...
Novavax losses widen on research costs
Washington Business Journal
Rockville-based Novavax Inc. reported a wider loss for its latest quarter, as research and development and payroll costs rose. Read More...
Emergent quarterly earnings fall
Washington Business Journal
Rockville-based Emergent BioSolutions Inc. reported lower revenue and earnings for its latest quarter, but stands by its full-year forecast. Read More...
Vanda Pharmaceuticals posts profits again
Washington Business Journal
Rockville-based Vanda Pharmaceuticals Inc. posted its second straight quarterly profit after collecting revenue from a partnership with Novartis AG. Read More...
Susan G. Komen awards $2.6M to Baltimore researchers
Baltimore Business Journal
Susan G. Komen for the Cure awarded $2.6 million in research grants to Baltimore universities and hospitals, up from $1.5 million last year. Read More...
Amplimmune inches closer to potential exit with GlaxoSmithKline deal
Washington Business Journal
GlaxoSmithKline PLC’s alliance with Rockville-based biotech Amplimmune Inc. represents a “great validation” for the small firm’s work and brings it a step closer to a potential exit down the road, said Chief Business Officer Gary Fanger. Read More...
FDA gives blessing to Baltimore company's diabetes system
Gazette.com
A Baltimore company has won a key federal regulatory approval for its diabetes management software system, which it plans to start marketing early next year. Read More...
July
United Therapeutics back in black as revenue jumps 64%
Washington Business Journal
United Therapeutics Corp. returned to profitability in the second quarter as a wider offering of products boosted sales at the Silver Spring drug manufacturer 64 percent. Read More...
HGS revenue rises
Washington Business Journal
Rockville-based Human Genome Sciences Inc. reports a smaller quarterly loss and higher revenue on royalty payments and sales of an anthrax treatment to the government. Read More...
EntreMed keeps Nasdaq listing
Washington Business Journal
A month after shareholders approved a reverse stock split to boost its stock price, Rockville-based EntreMed Inc. says it has been notified by Nasdaq that it is now in compliance to keep its Nasdaq Capital Market listing. Read More...
Precision Antibody Selected to Provide Antibody Characterization for NCI
Press Release
Second contract awarded to company as part of NCI initiative to improve monocional antibody reagents for proteomics research. Read More
Lawrence Bruder joins Noxilizer as President & Chief Executive Officer
Press Release
Baltimore, July 19, 2010 -- Noxilizer, Inc., a developer of next generation gas sterilization technology for hospitals and life science companies, announced the appointment of Lawrence Bruder as President & Chief Executive Officer. Read More
Baltimore facility key to Emergent's plan to expand beyond biodefense
WashingtonPost.com
Rockville-based Emergent BioSolutions is planning to make major renovations to a 55,000-square-foot facility in Baltimore that the pharmaceutical company said is key to its plans to expand beyond the biodefense sector. Read More...
Maryland Governor Martin O'Malley Leads Ribbon Cutting Ceremony at Emergent's Baltimore Manufacturing Facility
Press Release
Emergent BioSolutions Inc. today held a ribbon cutting ceremony, led by Governor Martin O'Malley and Fuad El-Hibri, Emergent's chairman and chief executive officer, to mark the formal opening of Emergent Manufacturing Operations Baltimore. Read More...
Emergent sees 120 jobs at new facility
Washington Business Journal
Rockville-based Emergent BioSolutions Inc. held a ribbon-cutting ceremony at a new manufacturing facility in Baltimore Friday, and says the plant could create as many as 120 new jobs over the next five years. Read More...
Emergent expansion deal worth up to $107 million
Gazette.net
Emergent BioSolutions of Rockville has won a federal contract worth up to $107 million to help develop and obtain regulatory approval for ramping up its Lansing, Mich., plant to produce 26 million doses annually of its anthrax vaccine.
Read More...
Nabi Biopharmaceuticals Completes Enrollment of First NicVAX Phase III Clinical Trial
Citybizlist.com
Nabi Biopharmaceuticals announced today that it has completed enrollment in the first Phase III clinical trial of NicVAX®(Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. Read More...
BioWatch: Martek shifts some operations from its Kentucky plant
Gazette.net
Martek Biosciences, which develops and produces nutritional products with essential fatty acids, is downsizing its manufacturing plant in Winchester, Ky., to cut costs. Read More...
Emergent BioSolutions wins $107M HHS contract
Washington Business Journal
Rockville-based Emergent BioSolutions Inc., the only producer of a government-approved anthrax vaccine, has won a government contract to ensure it can produce large quantities of it. Read More...
EntreMed gains on study results
Washington Business Journal
Rockville-based EntreMed Inc., moving its lead drug candidate forward with Phase 2 clinical trials to treat ovarian cancer, reports research shows promising results as a potential treatment for a deadly form of bone cancer as well. Read More...
Human Genome Sciences signs supply deal for Benlysta with Lonza
Washington Business Journal
Rockville-based Human Genome Sciences Inc., which is seeking approval to sell its new treatment for lupus in the United States and Europe, is taking steps to make sure it will have plenty of supply. Read More...
What Baltimore's biotech industry needs: an 'anchor'
The Baltimore Sun
Baltimore's biotechnology industry has made strides. Two biotech parks by the Johns Hopkins University and the University of Maryland now anchor the east and west sides of the city. A few dozen biotech startups have made their home here. But Baltimore's nascent biotech industry doesn't yet have a breakout company — a darling of venture capitalists and Wall Street that has grown past the risky and unprofitable startup phase to achieve a steady stream of revenue and products in the pipeline. Read More...
June
FDA delays decision on AZ's motavizumab
Fierce Biotech
AstraZeneca's MedImmune unit has received word from the FDA has delayed decision date for its review of motavizumab, an investigational monoclonal antibody being considered to help prevent serious respiratory syncytial virus, from June 24 to Aug. 27. Read More...
Two biotechs score $10M stock deals
Gazette.net
In recent days, two Rockville biotechs — Neuralstem and Rexahn Pharmaceuticals — have reported nailing down stock sales of $10 million each to institutional investors. Read More...
Neuralstem raises $10M
Washington Business Journal
Rockville-based Neuralstem Inc., which said in March it had enough funding to continue research through the first quarter of 2011, will add another $10 million to its bank account. Read More...
Emergent sells anthrax vaccine to allies
Washington Business Journal
Rockville-based Emergent BioSolutions Inc., which supplies anthrax vaccines to the U.S. government, has delivered doses of its BioThrax vaccine to governments of several allied nations. Read More...
United Therapeutics CEO Martine A. Rothblatt Sells $5.7M Worth of Shares
Citybizlist
A series of SEC filings reveal that Martine A. Rothblatt, founder, chairman and chief executive officer of United Therapeutics Corporation has sold more than $5.68 million worth of company shares so far this month. Read More...
Rockville scientist helps map louse genome
The Daily Record
In their quest to understand how life works, researchers reported Monday in the journal Proceedings of the National Academy of Sciences that they have sequenced the genome of the human body louse. Read More...
Arginetix and Immune Control Merge to Form Corridor Pharmaceuticals
BusinessWire
Arginetix, Inc. and Immune Control Inc. today announced their merger to form Corridor Pharmaceuticals, Inc., which will develop novel treatments for vascular diseases with an initial focus on pulmonary arterial hypertension (PAH).
Read More...
BioWatch: Gliknik gets new funding from Tech Council partner
Gazette.net
An up-and-coming Baltimore biopharm recently received an undisclosed financial boost from a venture capital partner of the Tech Council of Maryland. Gliknik, named 2009 Maryland Incubator Company of the Year, creates new therapies for patients with cancer and immune disorders by modulating the immune system to fight these diseases. Read More...
Cytomedix's wound-healing AutoloGel gets positive study results published
Washington Business Journal
Cytomedix Inc. is a small Rockville company that got some good news: Its AutoloGel wound-healing gel earned positive results in a study of 49 patients with chronic wounds -- applying the product 3.2 times across three weeks helped diminish 97 percent of the patients' wounds. Plus, those study results are being published in a peer-reviewed article in Ostomy Wound Management's June edition, often a penultimate for biotech companies. Read More...
GenVec explores sale, other options
Washington Business Journal
Gaithersburg-based GenVec Inc. has hired Walls Fargo Securities to decide whether it should sell all or part of the struggling company. Read More...
Human Genome Sciences hepatitis drug licensing unlikely
Washington Business Journal
Rockville-based Human Genome Sciences Inc. (NASDAQ: HGSI) says the U.S. Food and Drug Administration has raised concerns about the risk benefit assessment for its Zalbin drug for chronic hepatitis C. Although the the Biologics License Application review is ongoing, HGSI has concluded that licensure of this dosing regimen is unlikely. Read More...
Human Genome Sciences, GlaxoSmithKline seek European approval for lupus drug
Washington Business Journal
Rockville-based Human Genome Sciences Inc. and development partner GlaxoSmithKline PLC moved one step further toward marketing their lupus drug in Europe. Read More...
Montgomery officials eye reserves to lure biotech firms
WashingtonExaminer.com
Montgomery County's Department of Economic Development is seeking $2 million from the county's rainy day fund to attract biotech companies. Read More...
MedStar Health wins $7.3M research contract from NIH
Baltimore Business Journal
The research arm of MedStar Health has been awarded a $7.3 million contract from the National Institutes of Health. Read More...
Former execs at two local biotechs create a new one
Washington Business Journal
Alumni from two local biotech companies are teaming up to form Noble Life Sciences Inc., a contract research company. Read More...
FDA committee votes down MedImmune drug
Washington Business Journal
A Food and Drug Administration committee has recommended the agency reject MedImmune LLC’s marketing application for its latest drug offering for pediatric patients, delivering a painful blow to the Gaithersburg drug giant. Read More...
RegeneRx raises $4.5M in offering
Washington Business Journal
Rockville-based RegeneRx Biopharmaceuticals Inc. netted a total of $4.5 million from a secondary offering of stock and warrants after underwriters exercised their option to buy additional shares. Read More...
May
Ex-MedImmune exec sues company, questions testing
Washington Business Journal
A former MedImmune employee has sued the Gaithersburg biotech for $10 million, claiming it fired him for questioning the test results for what has long been anticipated to be the company’s most promising next billion-dollar drug. Read More...
Cell-ing Montgomery biotech
Washington Business Journal
The creation of a synthetic cell by a Montgomery County biotechnology research nonprofit last week could be a boon to research in the county while creating questions for government agencies and bioethicists. Read More...
Commissioner: Emergent should repay $250K loan
Gazette.net
A Rockville biodefense company's decision to expand in Baltimore rather than Frederick has prompted a county commissioner to seek a $250,000 loan repayment from the company. Read More...
Novavax appoints Mark Thornton as chief medical officer
Washington Business Journal
Rockville-based Novavax Inc. has tapped Mark Thornton to lead its vaccine clinical development programs as its new senior vice president for development and chief medical officer. Read More...
First Self-Replicating, Synthetic Bacterial Cell Constructed by J. Craig Venter Institute Researchers
J. Craig Venter Institute
Researchers at the J. Craig Venter Institute (JCVI), a not-for-profit genomic research organization, published results today describing the successful construction of the first self-replicating, synthetic bacterial cell. Read More...
Emergent moves ahead with new anthrax drug
Washington Business Journal
Rockville-based Emergent BioSolutions Inc. will advance to human testing for its drug designed to treat people already exposed to anthrax, after winning regulatory approval to advance. Read More...
NewsWatch: Dataprise CEO, Emergent win Tech Council honors
Gazette.net
David Eisner, president and CEO of Dataprise of Rockville, has been named Executive of the Year by the Tech Council of Maryland. Dataprise provides information technology services for small- and medium-sized businesses.
Read More...
GenVec receives Nasdaq warning again
Washington Business Journal
Gaithersburg-based GenVec, whose stock has tumbled this year after pulling the plug on one of its lead cancer treatments, has been notified that its stock price no longer meets Nasdaq Stock Market requirements. Read More...
Sucampo Pharmaceuticals narrows loss
Washington Business Journal
Bethesda-based Sucampo Pharmaceuticals Inc. narrowed its loss in the first quarter as it reined in research and development costs. Sucampo had a first-quarter net loss of $300,000, or 1 cent per diluted share, compared with a net loss $1.8 million, or 4 cents per diluted share, a year earlier.
Read More...
Novavax loss widens on research costs
Washington Business Journal
Rockville-based Novavax Inc. reports a wider quarterly loss after spending more on research and development of its influenza vaccines. The company's fiscal first quarter loss was $11.4 million, or 11 cents per share, compared to a net loss of $8.3 million, or 12 cents per share in the same quarter a year ago.
Read More...
Industry, public officials pitch state at BIO convention in Chicago
Gazette.net
Maryland's contingent of about 400 officials at the Biotechnology Industry Organization's annual International Convention in Chicago this week was heavy on private-sector participation. Large companies such as MedImmune and Human Genome Sciences sent representatives. Read More...
Live From BIO: Burrill: Focus on patients, not molecules
Fierce Biotech
The biopharma industry needs to focus less on molecules and more on patients. That was one of the key messages in Steven Burrill's annual state of the industry report presented at BIO earlier this week. Read More...
Live From BIO: Vaccines in the 21st century
Fierce Biotech
With new pathogens coming to the fore, new vaccines are absolutely still necessary, an expert panel said Tuesday at the BIO 2010 convention. But while opportunities exist, so do a number of challenges. Read More...
Baltimore's BioMarker wins $1M grant
Baltimore Business Journal
The National Cancer Institute has awarded Baltimore’s BioMarker Strategies $1 million to help fund development of a diagnostic test that could help doctors treat cancer patients. Read More...
Micromet loss expands to $16.3M
Washington Business Journal
Bethesda-based Micromet Inc., which just completed a stock offering to fund its drug research, saw its loss balloon 50-fold last quarter as research and development costs piled up and the company took a non-cash charge.
Read More...
Vanda Pharmaceuticals turns a profit
Washington Business Journal
Rockville-based Vanda Pharmaceuticals Inc. logged its first product sales revenue in the first quarter this year, resulting in its first-ever quarterly profit, albeit lower than analysts had expected. Read More...
Live From BIO 2010: Hamburg discusses advancing regulatory science
Fierce Biotech
FDA Commissioner Margaret Hamburg addressed attendees at the BIO 2010 conference, where she emphasized the need to strengthen regulatory science to evaluate the safety and efficacy of products more quickly to get them to the people. Without strengthening regulatory science, many promising technologies may be abandoned because there wasn't the know-how to see their potential. Read More...
April
United Therapeutics revenue up 63%
Washington Business Journal
United Therapeutics Corp. reported a 63 percent jump in revenues in the first quarter of 2010 to $128.9 million, up from $79.7 million for the first quarter of 2009. Read More...
ExonHit eyes RedPath for $22.5M
Gazette.net
ExonHit Therapeutics of Paris plans to pay $22.5 million in cash and stock for a Pittsburgh diagnostics company that will be brought under the wing of ExonHit's U.S. operations, whose headquarters are in Gaithersburg. Read More...
Montgomery County makes bid for medical institute and its 400 jobs
Washington Business Journal
As Montgomery County tries to woo a startup medical institute, and its 400 jobs, from Fairfax County, Va., county officials this week celebrated the $75 million expansion of a renowned research organization in Chevy Chase. The nonprofit Ignite Institute would have been Fairfax County's first major biotech research center. Read More...
Human Genome Sciences lupus drug misses one goal
Washington Business Journal
A day after withdrawing a European application to market its hepatitis drug, Rockville-based Human Genome Sciences reports disappointing long-term results for its drug to treat lupus. Read More...
BioMarker Strategies Named One of 20 Top Most Promising Startups
VCJ Yearbook
The editors of the Thomson Reuters Venture Capital Journal come up with the "VCJ 20", a list of the 20 most promising startup companies. Read More...
Human Genome Sciences withdraws European drug application
Washington Business Journal
Rockville-based Human Genome Sciences Inc. says development partner Novartis has withdrawn a marketing application in Europe for a hepatitis C treatment. Read More...
Virxsys ups financing goal
Washington Business Journal
Virxsys Corp. has upped the amount it hopes to raise in its next financing round by another $5 million, according to a regulatory document the Gaithersburg company recently filed. Read More...
Alper Biotech releases IHC diagnostic kits at the American Association for Cancer Research
Press Release
Alper Biotech announced today that their first in vitro monoclonal antibody-based immunohistochemistry (IHC) diagnostic kits will be launched at the American Association for Cancer Research (AACR) meeting to be held in Washington, DC, from April 17-21, 2010. The launch will consist of Alper’s first two IHC diagnostic kits. Read More...
Revenue up at Aeras Global TB Vaccine Foundation
Washington Business Journal
Aeras Global TB Vaccine Foundation earned 68 percent more in revenue in 2008, the most recent available financial data for the Rockville nonprofit, compared with the prior year, banking more than $50.8 million in net assets by the end of the year. The foundation released the figures April 12. Read More...
Cytomedix finds potential new revenue stream
Washington Business Journal
Cytomedix Inc., which lost about 89 percent of its revenue late last year when licensing agreements came to an end, has bought a new product line that generated $5 million in sales last year. Read More...
McCormick invests in research into health benefits of seasonings
Baltimore Sun
McCormick & Co., the world's largest spice company, has made research into potential health benefits of seasonings, ranging from cinnamon to turmeric and curry, a cornerstone of its business - not just a way to add zest to your picnic. Read More...
Rexahn seeks to advance Parkinson's drug
Washington Business Journal
Rockville-based Rexahn Pharmaceuticals Inc. is seeking Food and Drug Administration approval for human trials of an experimental drug to treat Parkinson's Disease. Read More...
March
Neuralstem funded through early 2011
Washington Business Journal
Rockville-based Neuralstem Inc., conducting its first human trials with stem cells to treat Lou Gehrig’s Disease, reports another annual loss, but says its current position will allow it to fund research at least through the first quarter of 2011. Read More...
Vanda Pharmaceuticals CBO leaves to start own venture
Washington Business Journal
Chip Clark has left his chief business officer post at Rockville-based Vanda Pharmaceuticals Inc. to start a new biotech venture, potentially in Montgomery County. Read More...
GenVec shuts down trials
Washington Business Journal
GenVec Inc. has decided to shut down its advanced clinical trials for its lead pancreatic cancer drug after it failed to show significant differences from standard care, delivering a massive blow to the Gaithersburg biotech and causing its stock price to lose nearly three-quarters of its value in Tuesday trading. Read More...
EntreMed gets Nasdaq listing extension
Washington Business Journal
Rockville-based EntreMed Inc. has gotten an extension to hit the required minimum stock price to prevent losing its place on the Nasdaq exchange. Read More...
Two firms, two university programs win GBC's 2010 Maryland Bioscience Awards
Greater Baltimore Committee
Leaders of two Columbia, Md. companies and the directors of university programs in Baltimore and College Park that conduct genome research and work to commercialize bioscience products have been named winners of the 2010 Maryland Bioscience Awards. Read More...
Tech Council of Maryland to Honor Winners of the 8th Annual Frederick County Technology Awards
Tech Council of Maryland
The Tech Council of Maryland (TCM) honored the winners of its 8th Annual Frederick County Technology Awards during a reception March 25th at Dutch's Daughter, Frederick, Maryland. Each year, TCM honors those companies in Frederick County that exemplify excellence in the technology community.
Read More...
Human Genome Sciences announces interim results of phase 2b monthly dosing trial of Zalbintm in patients with chronic hepatitis
Fierce Biotech
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBINTM (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. Read More...
Novavax rallies on swine flu vaccine
Washington Business Journal
Rockville-based Novavax Inc. reported positive results from Phase I of its two-phase clinical study in Mexico for its H1N1 vaccine, sending its stock up as much as 16 percent. Novavax is now officially seeking Mexican regulatory approval to market the vaccine. Read More...
Aeras nabs $12M for TB vaccine
Washington Business Journal
Rockville-based Aeras Global TB Vaccine Foundation has received about $12 million as its first-ever grant from the United Kingdom government. The local nonprofit, which is working on six new tuberculosis vaccine candidates, is one beneficiary in the U.K. Department for International Development’s new $18 million initiative to cut the number of tuberculosis deaths in the world’s poorest countries. Read More...
Lab Recyclers shifts warehouse to Frederick
Washington Business Journal
Lab Recyclers Inc., a supplier of lab instruments, furniture and equipment, has moved its warehouse from Gaithersburg to a new spot in Frederick. The 13-year-old Gaithersburg-based company, which serves biotech companies, is planting its warehouse within 9,000 square feet at 4527 Metropolitan Ct. in Frederick. Read More...
Nabi Biopharmaceuticals to repurchase shares
Washington Business Journal
Rockville-based Nabi Biopharmaceuticals said it plans to repurchase $60.9 million worth of its outstanding stock. The company, which is flush with cash and has sold or potentially partnered off all of its drug candidates, said its board has approved the measure. Read More...
Claire Fraser-Liggett to be inducted in Maryland's Women's Hall of Fame
UMBBioPark.com
Claire Fraser-Liggett, PhD, director of the Institute for Genome Sciences at the University of Maryland School of Medicine, is one of six trailblazing women who will be inducted into the Maryland Women’s Hall of Fame at an event in Annapolis on March 18. Read More...
Micromet nets $75M from stock offering
Washington Business Journal
Bethesda-based Micromet has completed a secondary stock offering of 11.5 million shares, with underwriters exercising their full option. Read More...
Human Genome Sciences announces results of randomized phase 2 trial of mapatumumab in non-small cell lung cancer
Fierce Biotech
Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). Read More...
Stem cells: Coast-to-coast collaboration under way
Gazette.net
More than 120 stem cell researchers from Maryland and California met in Baltimore on Friday as the two states took the next step in a development collaboration announced at the 2009 World Stem Cell Summit in September. Read More...
Micromet prices new stock offering
Washington Business Journal
Bethesda-based Micromet hopes to raise at least $65.5 million in a secondary stock offering. The company, whose research and development costs tripled last quarter, has priced its secondary offering at $7 per share. Read More...
Novavax loss widens on research
Washington Business Journal
Rockville-based Novavax Inc. reported wider quarterly and full year losses as it ramps up clinical trials for its experimental vaccines. Read More...
Human Genome Sciences teams with Swedish firm on research
Washington Business Journal
Rockville-based Human Genome Sciences Inc. and BioInvent International AB, a Swedish pharmaceutical research company, will work together on discovering potential new drugs. Read More...
Zyngenia to grow in Gaithersburg
Washington Business Journal
Biotech startup Zyngenia Inc. said it plans to grow its presence in Gaithersburg, thanks to up to $2.5 million in public funding. Zyngenia said it expects to raise its roughly 14 employee count to at least 20 people by the end of this year. Read More...
Nabi Biopharmaceuticals logs revenue from Glaxo sale
Washington Business Journal
Nabi Biopharmaceuticals realized $10.5 million in revenue in its fiscal fourth quarter after collecting development payments from GlaxoSmithKline PLC for its PentaStaph drug. Read More...
Micromet to sell more shares
Washington Business Journal
Bethesda-based Micromet Inc., whose research and development costs tripled last quarter, plans to sell more stock to the public in a secondary offering. The company will offer 10 million shares, with an additional 1.5 million offered to underwriters. Read More...
Human Genome Sciences names David Southwell CFO
Washington Business Journal
Days after Human Genome Sciences Inc.’s chief financial officer stepped down, the Rockville biotech has named a board member, David Southwell, as his replacement, effective March 22. Read More...
Nabi Biopharmaceuticals closes on GSK deal
Washington Business Journal
Nabi Biopharmaceuticals has closed on a licensing deal with GlaxoSmithKline PLC that will earn the Rockville biotech $40 million in upfront payments. The deal could result in as much as $460 million more in potential option fees and payments upon meeting certain regulatory, development and clinical milestones for NicVax and similar nicotine vaccine products. Read More...
Emergent BioSolutions revenue up 50%
Washington Business Journal
Sales of its anthrax vaccine to the U.S. government boosted revenue for Rockville-based Emergent BioSolutions Inc. by 50 percent. Read More...
Human Genome Sciences pays CFO Tim Barabe severance, gives execs big bonuses
Washington Business Journal
Human Genome Sciences Inc. will make severance payments to its soon-to-depart chief financial officer, even as the Rockville biotech’s board decided to award bonuses to its remaining executive officers. Read More...
Micromet loss swells
Washington Business Journal
Bethesda-based Micromet Inc. reported wider losses for its latest quarter as research and development costs tripled. The company, developing cancer treatments aimed at strengthening the body's own immune system cells, had a fourth quarter net loss. Read More...
Human Genome Sciences posts 300% increase in 4Q revenue
Washington Business Journal
Fourth-quarter revenue for Rockville-based Human Genome Sciences Inc. was more than three times what the company made during the same period a year earlier, helping it significantly narrow its quarterly loss and turn a full-year profit for the first time in 14 years. Read More...
Nabi Biopharmaceuticals shareholders OK GSK deal
Washington Business Journal
Nabi Biopharmaceuticals stockholders approved a licensing deal with GlaxoSmithKline PLC, giving it the first chance at owning the rights to the Rockville biotech’s last remaining product, a smoking cessation vaccine called NicVax. Read More...
Psyadon Pharmaceuticals starts drug trial on genetic disorder patients
Washington Business Journal
Federal regulators have accepted Psyadon Pharmaceuticals Inc.’s application to start testing the Germantown biotech’s drug in patients for the first time. Psyadon will begin testing its drug, ecopipam, at Emory University on an estimated six adults, adolescents and children, ages 6 to 65. Read More...
Human Genome Sciences CFO resigns
Washington Business Journal
Rockville-based Human Genome Sciences Inc. said its chief financial officer has resigned to pursue another opportunity. Timothy Barabe, who joined Human Genome Sciences as finance chief in 2006, announced his resignation March 1. Read More...
March vote could decide Nabi Biopharmaceuticals' future
Washington Business Journal
For years, Nabi Biopharmaceuticals has been a painful thorn in the sides of its shareholders. But in a matter of days, those holders are expected to endorse a licensing agreement that could help make the Rockville biotech their most lucrative investment ever. Read More...
February
Germantown's Psyadon tackles a 'terribly disfiguring' disease
Gazette.net
Almost a year and a half ago, Richard E. Chipkin landed an $8 million investment in his tiny bioscience company, changed its name and research focus, and licensed a compound that shows promise as a treatment for a debilitating genetic condition called Lesch-Nyhan disease. Lesch-Nyhan afflicts a relative handful of people in the United States. Read More...
United Therapeutics withdraws hypertension drug application in Europe
Washington Business Journal
Silver Spring-based United Therapeutics Corp. has pulled the plug on its European marketing application to sell Tyvaso, an inhaled version of its pulmonary arterial hypertension drug, because its chances for approval in the European market seemed unlikely. Read More...
Novavax says swine flu vaccine works
Washington Business Journal
Rockville-based Novavax Inc. says its experimental H1N1 vaccine showed positive results in clinical trials it has been conducting with patients in Mexico. Read More...
DHS extends GenVec vaccine contract
Washington Business Journal
Gaithersburg-based GenVec Inc. will continue to develop vaccines against foot-and-mouth disease for the Department of Homeland Security under a new contract worth as much as $4.5 million. Read More...
Novavax warned of Nasdaq non-compliance
Washington Business Journal
Rockville-based Novavax named a local biotech entrepreneur as its new executive chairman of its board -- and promptly was notified that it broke the Nasdaq listing's rules on independent board members. Read More...
Neuralstem raises more needed cash, regains AMEX compliance
Washington Business Journal
Neuralstem Inc. said it’s raised $5.2 million since the start of the year as the small Rockville biotech pushes forward on its first human trials of a spinal cord injury treatment. Read More...
EntreMed receives orphan designation for leukemia drug
Washington Business Journal
Rockville-based EntreMed Inc. has announced that the Food and Drug Administration has granted orphan drug designation for the company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia. Read More...
United Therapeutics sees revenue leap
Washington Business Journal
With two new drugs on the market, Silver Spring-based United Therapeutics Corp. rung up nearly 44 percent more in fourth-quarter revenue last year compared with 2008. Read More...
Vanda Pharmaceuticals earns first revenue, widens loss
Washington Business Journal
Rockville-based Vanda Pharmaceuticals Inc. brought in some of its first-ever revenue in the fourth quarter of last year, a period when it signed a deal with a larger pharmaceutical to sell its first product on pharmacy shelves. Read More...
Biotech startup lands $1.5M in public funds
The Examiner
Montgomery County officials gave a Gaithersburg company a $1.5 million taxpayer-funded grant based on support for the startup by venture capitalist, David Mott. Read More...
Novavax, Inc. (NVAX) Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
BioSpace
Novavax, Inc. announced today that the company has decided to discontinue negotiations in its pursuit of the previously announced collaboration with ROVI Pharmaceuticals to develop Novavax's virus-like-particle (VLP)-based vaccines against influenza in the country of Spain. Read More...
Researchers Report that Tβ4 Increases Skeletal Muscle and May Have a Role in the Treatment of Duchenne Muscular Dystrophy
BusinessWire
REGENERX BIOPHARMACEUTICALS, INC. announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with Tβ4, showed a significant increase in skeletal muscle regenerating fibers compared to untreated mice. Read More...
Lung Rx LLC, A Subsidiary Of United Therapeutics Corporation, And mondoBIOTECH holding AG Announce Today a Global Strategic Partnership Agreement for the Development Of Aviptadil Platform
BusinessWire
After completion by mondoBIOTECH (SIX: RARE) of a Phase II study where inhaled Aviptadil was shown to have a unique safety profile and promising signals of long term efficacy over currently approved therapies in patients affected by Pulmonary Arterial Hypertension (PAH), United Therapeutics Corporation’s Lung Rx subsidiary and mondoBIOTECH finalized a global strategic partnership focused on the development of Aviptadil for a range of indications, as for example PAH, Sarcoidosis, Idiopathic Pulmonary Fibrosis (IPF) and Acute Respiratory Distress Syndrome (ARDS). The platform can generate more than 1 billion CHF turnover. Read More...
Human Genome Sciences Names Scott Habig Vice President, Sales
BusinessWire
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Scott Habig has joined the Company as Vice President, Sales, reporting to Kevin P. McRaith, Vice President, Sales and Marketing, HGS. Mr. Habig was most recently Vice President, Sales, at Centocor Ortho Biotech, a subsidiary of Johnson & Johnson. Read More...
Rexahn Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
BusinessWire
Rexahn Pharmaceuticals, Inc. today announced that it will present at the 12th Annual BIO CEO & Investor Conference on February 9, 2010, at 11:30 a.m. Eastern Standard Time at The Waldorf=Astoria, New York City. Read More...
back to top
January
Supernus Announces Positive Results from Phase IIa Clinical Trial for SPN 810 in Children with ADHD and Serious Conduct Problems
BusinessWire
Supernus Pharmaceuticals Inc., today announced that its Phase IIa U.S. clinical trial for SPN 810 in children with ADHD and persistent serious conduct problems met the primary endpoints of safety and tolerability, as well as showed statistically significant reduction versus baseline in conduct problems across all doses. Read More...
Improved Optimization and Development of Ion Channels for Cell-Based Assays MaxCyte Webinar with Case Studies from BioFocus
BusinessWire
MaxCyte, Inc., the leader in scalable, high performance cell loading systems, will host case study discussions with industry experts demonstrating how the MaxCyte® STX™ Scalable Transfection System improves transfection of cells with ion channels for cell-based assays for drug discovery screening. Read More...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2009 Financial Results and Conduct a Conference Call on March 4, 2010
BusinessWire
Company management will host a conference call at 5:00 pm Eastern on March 4, 2010 to discuss the financial results for the fourth quarter and full twelve months of 2009, recent business developments and the forecast for 2010. Read More...
GenVec to raise $28M from stock sale
Washington Business Journal
GenVec Inc. is raising $28 million from a stock sale that reflected some of the highest sale prices in years, but offered at enough of a discount to send the Gaithersburg biotech’s stock price sinking in Wednesday’s trading. Read More...
RegeneRx Biopharmaceuticals, Inc. Moving to New Corporate Office Space
Business Wire
REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that it is moving its corporate headquarters from Bethesda, Maryland to the Maryland I-270 Technology Corridor in Rockville, Maryland, effective January 22, 2010. The company’s offices will be closed on that day to complete the move. Read More...
EntreMed aims to prevent stock delisting
Washington Business Journal
EntreMed Inc. said it will appeal a federal regulatory agency’s decision, which could delist the Rockville biotech’s stock from a Nasdaq exchange in a matter of days. Read More...
Martek to Acquire Amerifit Brands for $200M
Citybizlist
Martek Biosciences Corporation (NASDAQ:MATK) has entered into an agreement to purchase Amerifit Brands Inc., a consumer health and wellness company, from Charterhouse Group, Inc. in an all-cash transaction valued at $200 million. Read More....
BioElectronics Files Application with FDA for Reclassification – Company to File PMA Application
Business Wire
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it filed an application with the U.S. Food and Drug Administration (FDA) for reclassification to Class II of its existing device which was given FDA Class III approval in 2002. Read More...
Xceleron Achieves Significant Growth in 2009 - Raises Funds and Expands Core Capabilities to Fuel Further Growth
Business Wire
Xceleron, a leader in providing drug developers with early insights from human data, announced today that it is expanding its bioanalytical capabilities following a year of strong growth. Read More....
Novartis, GenVec to develop hearing-loss treatment in $214M deal
Triangle Business Journal
Gaithersburg, Md.-based biopharmaceutical firm GenVec announced Tuesday that it will collaborate with Novartis AG to develop a hearing loss treatment in a research and licensing deal that eventually could be worth as much as $213.6 million. Read More...
Key Event Occurs in GenVec's PACT Trial
PRNewswire
GenVec, Inc. announced today that 184 events (deaths) have occurred in its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade™ (PACT) in patients with locally advanced pancreatic cancer. This event, which represents two-thirds of the total events expected in the trial, triggers the next interim analysis of overall survival in the trial. GenVec expects data from this interim analysis to be available in approximately 10-12 weeks. Read More...
Centauri Labs Receives Department of Defense ELAP Accreditation
Business Wire
Centauri Labs, an environmental testing company with comprehensive analytical testing services and innovative technical expertise in all aspects of environmental monitoring, receives accreditation under the new Department of Defense Environmental Laboratory Approval Program (ELAP). Read More....
Omnia Biologics and Biotech Experts Sign Development Agreement
Business Wire
Omnia is a contract manufacturer focused on process development and clinical trials material manufacturing of innovative biopharmaceuticals. Biotech Experts accelerates development of new biological therapies for life-threatening diseases by providing consulting services to the biotech community. Biotech Experts represents decades of experience in the biotech industry. Read More...
Emergent BioSolutions Announces R. Don Elsey, Chief Financial Officer, to Join Board of Directors of MdBio Foundation
Business Wire
Emergent BioSolutions Inc. announced that R. Don Elsey, chief financial officer (CFO) and senior vice president of finance and administration, has joined the board of directors of the MdBio Foundation. Read More...
Human Genome Sciences Reports Increasing Momentum toward Commercialization and Announces 2010 Goals at JPMorgan Healthcare Conference
Business Wire
Human Genome Sciences, Inc. today announced its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C. Read More....
Emergent BioSolutions Provides Preliminary 2009 Financial Results and Guidance for 2010
Business Wire
Emergent BioSolutions Inc. announced today preliminary, unaudited financial results for 2009 and guidance for 2010. Read More....
Vanda launches schizophrenia drug Fanapt
Gazette.Net
Fanapt, the schizophrenia treatment whose approval last year by the Food and Drug Administration turned around the fortunes of once-struggling Vanda Pharmaceuticals, has hit the market. Read More...
Emergent BioSolutions lowers its debt payments
Washington Business Journal
Rockville-based Emergent BioSolutions Inc. has refinanced a more than 2-year-old loan to reduce its monthly payments by half. Read More...
Biotech firm lands $2.1M funding
Baltimore Business Journal
A biotechnology firm in East Baltimore has raised $2.1 million of a $10 million equity offering, according to a regulatory filing with the Securities and Exchange Commission. Read More...
Biofuel startup to expand production in Baltimore
Baltimore Sun
A biofuel startup with a Baltimore production plant is planning to expand and hire this year, as orders for its cleaner-burning fuel grow, according to the firm's chief executive officer. Read More....
Bioactive Surgical Inc.
Baltimore Business Journal
Rick Spedden’s surgery to fix his ruptured Achilles tendon left him in some pain. But it also left him with a business partner and a burgeoning company.
Read More....
Fyodor Biotechnologies Corp.
Baltimore Business Journal
As a child growing up in Nigeria, Eddy C. Agbo saw first hand the devastating effects of malaria. Read More....
Claire M. Fraser-Liggett, Institute for Genome Sciences
Washington Post
In my senior year of college, I did research with a doctor that got me excited about what a career in medical research was all about. Read More...